NVCRNovoCure Ltd
$17.20
$1.42
(9.00%)
Closed $17.20
$0.11
(0.64%)
After Hours
EarningsJul 23
Mkt Cap$1.99B
Vol1.95M
NovoCure's Cancer Treatment Device Option Pax Gets European Approval
NVCR secures European approval for Optune Pax, expanding access to its pancreatic cancer treatment after strong late-stage trial results.
Zacks
Novocure to Report Second Quarter 2026 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 23, to discuss the companys financial results for the three-month period...
Business Wire
Novocures Optune Pax Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
Novocure (NASDAQ: NVCR) announced today that Optune Pax has received CE (Conformit Europenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline...
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP...
PR Newswire
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
Key PointsHeartFlow uses AI-driven software to transform cardiac diagnostics through non-invasive heart scans...
Nasdaq News: Markets
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
Key PointsNovoCure maintains a commercialized revenue base through its proprietary Tumor Treating Fields oncology platform...
Nasdaq News: Markets
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limited (NovoCure or the Company) (NASDAQ: NVCR) for violations of the securities laws. The investigation focuses on whether the Company issued false...
Business Wire
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Key PointsAmgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications...
Nasdaq News: Markets
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) PR Newswire NEW YORK,, June 18, 2026 Novocure reported its...
PR Newswire
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks
Novocure's Phase 3 TRIDENT trial missed its primary survival endpoint in glioblastoma but confirmed TTFields safety.read more...
Benzinga
<
1
2
...
>